Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883238 | 0.80 | PDE5A (0.43) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL22114191 | 0.79 | GABRA1 (0.37) | PDE10AS1PR4 | |
| SCHEMBL8184699 | 0.79 | KMT2A (0.42) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL27919960 | 0.78 | TRPV4 (0.40) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL29122012 | 0.78 | PDE5A (0.41) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL7995744 | 0.78 | ABCB11 (0.40) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL22114190 | 0.76 | GABRA1 (0.42) | PDE10APDE4DS1PR4SLC6A2SLC6A4 | |
| SCHEMBL3430430 | 0.75 | L3MBTL1 (0.39) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL8273112 | 0.73 | ROCK2 (0.39) | ALDH1A1MAPTHPGDHTTTDP1 | |
| SCHEMBL3431729 | 0.73 | TRPM8 (0.40) | PDE10AALDH1A1MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | PDE10A 2832/4885PDE4D 2392/4885S1PR4 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.